Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). AVITA Medical's share price for the quarter that ended in Dec. 2023 was $13.72. AVITA Medical's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 25.68 Mil. Therefore, AVITA Medical's market cap for the quarter that ended in Dec. 2023 was $352.36 Mil.
AVITA Medical's quarterly market cap
declined
from Jun. 2023 ($432.86 Mil) to Sep. 2023 ($373.30 Mil) and
declined
from Sep. 2023 ($373.30 Mil) to Dec. 2023 ($352.36 Mil).
AVITA Medical's annual market cap
declined
from Jun. 2021 ($510.86 Mil) to Dec. 2022 ($166.38 Mil) but then
increased
from Dec. 2022 ($166.38 Mil) to Dec. 2023 ($352.36 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. AVITA Medical's Enterprise Value for Today is $173.17 Mil.
AVITA Medical Market Cap Historical Data
The historical data trend for AVITA Medical's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AVITA Medical's Market Cap
For the Medical Devices subindustry, AVITA Medical's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVITA Medical's Market Cap Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's Market Cap distribution charts can be found below:
* The bar in red indicates where AVITA Medical's Market Cap falls into.
AVITA Medical Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
AVITA Medical's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVITA Medical (NAS:RCEL) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
AVITA Medical Market Cap Related Terms
Thank you for viewing the detailed overview of AVITA Medical's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
AVITA Medical (AVITA Medical) Business Description
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RCEL has been successfully added to your 